Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal


Classification: A

Drug products: Axura, Ebixa, Ebixa®, Marbodin, Memantin Ebb, Memantin Orion, Memantin STADA, Memantine Accord, Memantine LEK, Memantine Mylan, Memantine ratiopharm, Memantine Sandoz, Memantine-Merz, Mentixa, Nemdatine

ATC code: N06DX01

Substances: memantine, memantine hydrochloride


No studies have shown differencs in effect between men and women treated with memantine.
The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokinetics and dosing

Following a multiple dose administration of memantine 20 mg twice a day, Cmax and AUC were approximately 45% higher in women than in men. However, there were no differences in Cmax or AUC when body weight was taken into account [1]. In a pharmacokinetic study (34 men, 74 women), men had higher oral clearance (CL/F) [4]. Despite the pharmacokinetic differences of memantine, the clinical studies have shown effect with similar doses in men and women, and no sex differentiation in dosing has been suggested [5].


Other information

An American retrospective data analysis investigated the relationship between adherence to oral AD therapy (rivastigmine, donepezil, galantamine or memantine) and other variables. Male AD patients were approximately 18% more likely to be adherent to index oral AD therapy than female patients [7].In a retrospective analysis of effect of memantine with or without vitamin E (15 men, 28 women), no differences between men and women were shown [6].

Adverse effects

No studies with a clinically relevant sex analysis regarding adverse effects of memantine have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2013-05-14


  1. Namenda (memantine). DailyMed [www]. US National Library of Medicine. [updated 2013-01-01, cited 2013-05-14]. länk
  2. Borah B, Sacco P, Zarotsky V. Predictors of adherence among Alzheimer's disease patients receiving oral therapy. Curr Med Res Opin. 2010;26:1957-65. PubMed
  3. Noetzli M, Guidi M, Ebbing K, Eyer S, Wilhelm L, Michon A et al. Population pharmacokinetic study of memantine: effects of clinical and genetic factors. Clin Pharmacokinet. 2013;52:211-23. PubMed
  4. Memantine. Summary of Product Characteristics. European Medicines Agency; 2013.
  5. Annweiler C, Herrmann FR, Fantino B, Brugg B, Beauchet O. Effectiveness of the combination of memantine plus vitamin D on cognition in patients with Alzheimer disease: a pre-post pilot study. Cogn Behav Neurol. 2012;25:121-7. PubMed
  6. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-30.] länk

Authors: Linnéa Karlsson Lind, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson